NEW YORK--(BUSINESS WIRE)--The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of TransEnterix, Inc. (“TransEnterix” or the “Company”) (NYSE MKT:TRXC) between February 10, 2016 and May 10, 2016.
You are hereby notified that a class action has been commenced in the USDC for the Eastern District of North Carolina. If you purchased or otherwise acquired TransEnterix securities between February 10, 2016 and May 10, 2016, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
TransEnterix developed The SurgiBot ™ System, a surgical platform designed to be minimally invasive and allow for multiple instruments to be introduced and deployed through an incision. The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that (a) there were deficiencies within the Company’s 510(k) application to the Food and Drug Administration which undermined the likelihood that the SurgiBot would receive FDA clearance; (b) that as a result of these deficiencies, TransEnterix would be unable to commercialize the SurgiBot in 2016; and (c) consequently, the Company’s ability to obtain approval for and commercialize its other robotic surgery platforms in the U.S. would be impaired.
If you suffered a loss in TransEnterix you have until August 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.